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ABSTRACT
Objective Randomized controlled trials (RCTs)
have recently compared intramuscular 17α-hydroxy-
progesterone caproate (17-OHPC) with vaginal proges-
terone for reducing the risk of spontaneous preterm birth
(SPTB) in singleton gestations with prior SPTB. The
aim of this systematic review and meta-analysis was to
evaluate the efficacy of vaginal progesterone compared
with 17-OHPC in prevention of SPTB in singleton
gestations with prior SPTB.
Methods Searches of electronic databases were performed
to identify all RCTs of asymptomatic singleton gestations
with prior SPTB that were randomized to prophylactic
treatment with either vaginal progesterone (intervention
group) or intramuscular 17-OHPC (comparison group).
No restrictions for language or geographic location were
applied. The primary outcome was SPTB < 34weeks.
Secondary outcomes were SPTB <37weeks, < 32weeks,
< 28weeks and < 24weeks, maternal adverse drug
reaction and neonatal outcomes. The summary measures
were reported as relative risk (RR) with 95% CI. Risk of
bias for each included study was assessed.
Results Three RCTs (680 women) were included. The
mean gestational age at randomization was about
16weeks. Women were given progesterone until 36weeks
or delivery. Regarding vaginal progesterone, one study
used 90mg gel daily, one used 100mg suppository daily
and one used 200mg suppository daily. All included
RCTs used 250mg intramuscular 17-OHPC weekly in
the comparison group. Women who received vaginal
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progesterone had significantly lower rates of SPTB
< 34weeks (17.5% vs 25.0%; RR, 0.71 (95% CI,
0.53–0.95); low quality of evidence) and<32weeks
(8.9% vs 14.5%; RR, 0.62 (95% CI, 0.40–0.94); low
quality of evidence) compared with women who received
17-OHPC. There were no significant differences in the
rates of SPTB < 37weeks, < 28weeks and<24weeks.
The rate of women who reported adverse drug reactions
was significantly lower in the vaginal progesterone group
comparedwith the 17-OHPC group (7.1% vs 13.2%; RR,
0.53 (95% CI, 0.31–0.91); very low quality of evidence).
Regarding neonatal outcomes, vaginal progesterone was
associated with a lower rate of neonatal intensive care
unit admission compared with 17-OHPC (18.7% vs
23.5%; RR, 0.63 (95% CI, 0.47–0.83); low quality of
evidence). For the comparison of 17-OHPC vs vaginal
progesterone, the quality of evidence was downgraded for
all outcomes by at least one degree due to imprecision
(the optimal information size was not reached) and
by at least one degree due to indirectness (different
interventions).
Conclusions Daily vaginal progesterone (either suppos-
itory or gel) started at about 16weeks’ gestation is a
reasonable, if not better, alternative to weekly 17-OHPC
injection for prevention of SPTB in women with singleton
gestations and prior SPTB. However, the quality level of
the summary estimates was low or very low as assessed
by GRADE, indicating that the true effect may be, or is
likely to be, substantially different from the estimate of
the effect. Copyright © 2016 ISUOG. Published by John
Wiley & Sons Ltd.
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INTRODUCTION
Spontaneous preterm birth (SPTB) remains the number
one cause of perinatal mortality in many countries, includ-
ing the USA. Prior SPTB is one of the most important risk
factors for SPTB; women with prior SPTB have about an
18–54% risk of recurrent preterm birth1,2. In singleton
gestations with prior SPTB at 20 to 36 + 6 weeks’ ges-
tation, intramuscular 17α-hydroxyprogesterone caproate
(17-OHPC), preferably started at 16–20 weeks until
36 weeks, has been recommended3,4. This is based on tri-
als showing that 250 mg 17-OHPC weekly is associated
with significantly lower incidences of recurrent SPTB and
adverse neonatal outcomes compared with placebo5,6.
However, several randomized controlled trials (RCTs)
have also shown the efficacy of vaginal progesterone in
reducing the risk of SPTB in singletons with prior SPTB,
compared with placebo6.
The aim of this meta-analysis was to evaluate the
efficacy of vaginal progesterone compared with 17-OHPC
in prevention of SPTB in asymptomatic singleton
gestations with prior SPTB.
METHODS
Eligibility criteria
This meta-analysis was performed according to a
protocol recommended for systematic reviews7. The
research protocol was designed a priori, defining methods
for a search of the literature, including examining
articles and extracting and analyzing the data. Searches
were performed in MEDLINE, OVID, Scopus, Clini-
calTrials.gov, the PROSPERO International Prospective
Register of Systematic Reviews, Scielo, EMBASE and
the Cochrane Central Register of Controlled Trials with
the use of a combination of keywords and text words
related to ‘preterm birth’, ‘preterm delivery’, ‘singleton’,
‘cervical length’, ‘progesterone’, ‘progestogens’, ‘vaginal’,
‘17-alpha-hydroxy-progesterone caproate’ and ‘intra-
muscular’, from inception of each database to January
2016. No restrictions for language or geographic location
were applied.
Study selection
We included all RCTs of asymptomatic singleton gesta-
tions with prior SPTB that were randomized to prophy-
lactic treatment with either vaginal natural progesterone
(intervention group) or intramuscular 17-OHPC (compar-
ison group). Exclusion criteria included quasirandomized
trials (i.e. trials in which allocation was done on the
basis of a pseudorandom sequence, e.g. odd/even hospital
number or date of birth, alternation) and trials involving
women with short cervical length (CL) or with preterm
labor at the time of randomization. Trials of women with
multiple gestations were also excluded.
Risk of bias
The risk of bias in each included study was assessed
using the criteria outlined in the Cochrane Handbook
for Systematic Reviews of Interventions7. Seven domains
related to risk of bias were assessed in each included trial
since there is evidence that these issues are associated with
biased estimates of treatment effect: (1) random sequence
generation; (2) allocation concealment; (3) blinding of
participants and personnel; (4) blinding of outcome
assessment; (5) incomplete outcome data; (6) selective
reporting; and (7) other bias. Studies were categorized as
‘low risk’, ‘high risk’ or ‘unclear risk’ of bias by the review
authors7.
For this review, the quality of the evidence was assessed
using the GRADE approach in order to assess the quality
of the body of evidence relating to the primary and
secondary outcomes. GRADEpro Guideline Development
Tool was used to import data from Review Manager 5.3
(The Nordic Cochrane Centre, Cochrane Collaboration,
Copenhagen, Denmark) in order to create ‘Summary of
findings’ tables. A summary of the intervention effect and
a measure of quality for each of the above outcomes
was produced using the GRADE approach. The evidence
can be downgraded from ‘high quality’ by one level for
serious (or by two levels for very serious) limitations,
depending on assessments for risk of bias, indirectness
of evidence, serious inconsistency, imprecision of effect
estimates or potential publication bias. The quality of
the evidence (and its interpretation) was judged as
follows: high quality (further research is very unlikely
to change our confidence in the estimate of effect),
moderate quality (further research is likely to have an
important impact on our confidence in the estimate of
effect and may change the estimate), low quality (further
research is very likely to have an important impact on our
confidence in the estimate of effect and is likely to change
the estimate), very low quality (there is considerable
uncertainty about the estimate). The judgments about
quality were justified, documented and incorporated
into the reporting of results for primary and secondary
outcomes8.
Data abstraction
All analyses were done using an intention-to-treat
approach, evaluating women according to the treatment
group to which they were randomly allocated in the
original trials. The primary outcome was incidence
of SPTB < 34 weeks. Secondary outcomes were SPTB
< 37 weeks, < 32 weeks, < 28 weeks and <24 weeks,
maternal adverse drug reaction (i.e. number of women
who experienced adverse drug reaction) and neonatal
outcomes including birth weight (in grams), admission
to neonatal intensive care unit (NICU), respiratory
distress syndrome (RDS) (either transient tachypnea of the
newborn or severe RDS), bronchopulmonary dysplasia
(BPD), intraventricular hemorrhage (IVH) (Grade 3 or
4), severe necrotizing enterocolitis (NEC) (Grade 3 or
Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2017; 49: 315–321.
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4), neonatal sepsis (culture-proven sepsis) and perinatal
death. Perinatal death was defined as either fetal mortality
(i.e. fetal death after 20 weeks) or neonatal mortality (i.e.
death of a live-born baby within the first 28 days). All
authors of the original trials were contacted in order to
obtain missing data where possible.
Data analysis
The data analysis was completed using Review Manager
5.37. The completed analyses were then compared
and any difference was resolved with review of the
entire data and independent analysis. The summary
measures were reported as summary relative risk (RR)
or as summary mean difference (MD) with 95% CI,
using the random-effects model of DerSimonian and
Laird. I2 (Higgins I2) greater than 0% was used to
identify heterogeneity. Potential publication biases were
assessed statistically using Begg’s and Egger’s tests if ≥ 10
studies were available7. A P-value<0.05 was considered
statistically significant.
All review stages were conducted independently by two
reviewers (G.S., V.B.) who assessed inclusion criteria, risk
of bias, data extraction and data analysis. Disagreements
were resolved by discussion with a third reviewer
(A.K.).
The meta-analysis was reported following the Preferred
Reporting Item for Systematic Reviews and Meta-analyses
(PRISMA) statement9. Before data extraction, the
review was registered with the PROSPERO International
Prospective Register of Systematic Reviews (registration
no.: CRD42016033361).
RESULTS
Study selection and study characteristics
Five RCTs were assessed for eligibility10–14 and two
were excluded13,14, one because it compared vaginal
progesterone with intramuscular natural progesterone,
not 17-OHPC13, and the other because it explicitly
included women with preterm labor at the time of
randomization14 (Figure 1). Three RCTs, including a
total of 680 women, met the inclusion criteria and were
therefore included in the meta-analysis10–12. One study
included 74% of the total sample of the meta-analysis10.
The quality of RCTs included in our meta-analysis was
assessed by the Cochrane Collaboration’s tool7. All the
included studies had low risk of bias in ‘allocation
concealment’ and ‘random sequence generation’. Blinding
was considered difficult to achieve given the different
route of administration (vaginal vs intramuscular) and
none of the included RCTs was double blinded (Figure 2).
Publication bias could not be assessed given the
small (< 10) number of studies included. Statistical
heterogeneity within the trials was low (I2 = 0%) with
no inconsistency in risk estimate for the primary outcome
and for all secondary outcomes.
Records identified through 
database searching
(n = 29)
Records after duplicates removed
(n = 22)
Records screened
(n = 22)
Studies assessed for eligibility
(n = 5)
RCTs included in qualitative 
synthesis
(n = 3)
RCTs included in quantitative 
synthesis (meta-analysis)
(n = 3)
Records excluded based
on title or abstract
(n = 17)
RCTs excluded (n = 2)
    • Intramuscular natural
    progesterone not
         17-OHPC (n = 1)
    • Women with preterm
    labor (n = 1)
Figure 1 Flowchart of randomized controlled trials (RCTs)
identified for systematic review. 17-OHPC, 17α-hydroxy-
progesterone caproate.
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Figure 2 Risk of bias following The Cochrane Handbook7 in
individual randomized controlled trials (RCTs) (a) and across
RCTs (b) included in meta-analysis. Only first author of each study
is given. Risk of bias: , +, low; , ?, unclear; , −, high.
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The characteristics of the included trials are summarized
in Table 1. All studies included only asymptomatic
singleton gestations with prior SPTB between 16 + 0
and 36 + 6 weeks. Bafghi et al. also included women
without prior SPTB and with short CL on transvaginal
ultrasound12. We obtained the original database of this
study12 from the authors and excluded women without
prior SPTB from the analysis and those with a short CL on
transvaginal ultrasound, and included only asymptomatic
singleton gestations with prior SPTB between 16 + 0 and
36 + 6 weeks. Maher et al. explicitly excluded women
with a short cervix, defined as transvaginal sonographic
CL< 25 mm at the time of randomization10, whereas in
the RCT by Elimian et al., participants did not undergo
CL assessment11.
One RCT enrolled women between 14 and 18 weeks’
gestation10 and two between 16 and 20 weeks11,12.
The mean gestational age at randomization was about
16 weeks in both study groups.
All the included studies gave progesterone until
36 weeks or delivery. Of the 680 women included,
348 (51%) were randomized to vaginal progesterone
(intervention group), while 332 (49%) were randomized
to intramuscular 17-OHPC (comparison group).
Regarding the intervention (vaginal natural proges-
terone), Maher et al. used 90 mg gel daily10, Elimian
et al. used 100 mg suppository daily11 and Bafghi et al.
used 200 mg suppository daily12. All included trials used
250 mg intramuscular 17-OHPC weekly in the com-
parison group10–12. Additional unpublished data were
obtained from the authors of two of the included trials11,12
(Table 2).
Synthesis of results
Women who received vaginal progesterone had a signifi-
cantly lower rate of SPTB< 34 weeks (17.5% vs 25.0%;
RR, 0.71 (95% CI, 0.53–0.95); three trials, 680 partic-
ipants; Figure 3; low quality of evidence) and< 32 weeks
(8.9% vs 14.5%; RR, 0.62 (95% CI, 0.40–0.94); three
trials, 680 participants; low quality of evidence) compared
with women who received intramuscular 17-OHPC.
There were no significant differences in the rate of
SPTB< 37 weeks, <28 weeks and< 24 weeks between
the two groups. The proportion of women who reported
adverse drug reactions was significantly lower for those
receiving vaginal progesterone compared with 17-OHPC
(7.1% vs 13.2%; RR, 0.53 (95% CI, 0.31–0.91); two
trials, 535 participants; very low quality of evidence).
Regarding neonatal outcomes, vaginal progesterone was
associated with a lower rate of admissions to NICU
compared with 17-OHPC (18.7% vs 23.5%; RR, 0.63
(95% CI, 0.47–0.83); three trials, 680 participants; low
quality of evidence), while there were no differences for
other neonatal outcomes, including birth weight, and
incidences of RDS, BPD, IVH, NEC, sepsis and perinatal
death (Table 2).
DISCUSSION
Main findings
This pooled meta-analysis of three RCTs, including
680 women with a singleton gestation and prior SPTB,
showed that daily vaginal progesterone, started at about
16 weeks’ gestation, is associated with significantly lower
rates of SPTB< 34 weeks, adverse maternal side effects
and admission to NICU compared with intramuscular
17-OHPC.
Strengths and limitations
One of the strengths of our study is the inclusion of
RCTs in a specific population, i.e. singleton gestations
with prior SPTB. Prior SPTB is one of the most important
risk factors for preterm delivery1. Furthermore, no prior
meta-analysis has compared vaginal to intramuscular
progestogens. This meta-analysis included all trials
Table 1 Characteristics of randomized controlled trials comparing vaginal progesterone to intramuscular 17α-hydroxyprogesterone
caproate (17-OHPC) injection for prevention of recurrent spontaneous preterm birth (SPTB) included in systematic review and meta-analysis
Characteristic Maher (2012)10 Bafghi (2015)12 Elimian (2016)11 Total
Country Saudi Arabia Iran USA —
Sample size (n)* 502 (253 vs 249) 33 (16 vs 17) 145 (79 vs 66) 680 (348 vs 332)
Dose of vaginal progesterone 90 mg gel
daily
200 mg suppository
daily
100 mg suppository
daily
—
Dose of 17-OHPC 250 mg weekly 250 mg weekly 250 mg weekly 250 mg weekly
Exclusions for CL at randomization CL< 25 mm CL< 25 mm CL not assessed —
GA range at randomization (weeks) 14 + 0 to 18 + 6 16 + 0 to 20 + 6 16 + 0 to 20 + 6 14 + 0 to 20 + 6
GA at randomization (weeks, mean ± SD)* 15.3 ± 1.2 vs
15.4 ± 1.2
16.1 ± 2.9 vs
16.6 ± 1.2
17.9 ± 2.1 vs
18.0 ± 1.8
16.5 ± 2.1 vs
16.6 ± 1.4
(MD =−0.1
(95% CI, −0.3 to 0.1))
Primary outcome assessed SPTB< 34 weeks GA at delivery SPTB<37 weeks —
Only first author is given for each study. *Vaginal progesterone vs intramuscular 17-OHPC. CL, cervical length; GA, gestational age; MD,
mean difference.
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Table 2 Primary and secondary outcomes of randomized controlled trials comparing vaginal progesterone with intramuscular
17α-hydroxyprogesterone caproate (17-OHPC) injection for prevention of recurrent spontaneous preterm birth (SPTB) included in
meta-analysis
Outcome
Maher (2012)10
(n =253 vs 249)
Bafghi (2015)12
(n =16 vs 17)
Elimian (2016)11
(n = 79 vs 66)
Total
(n = 348 vs 332)
RR or MD‡
(95% CI)
SPTB<37 weeks 83 (32.8) vs 88 (35.3) 5 (31.3) vs 6 (35.3)* 30 (38.0) vs 29 (43.9) 118 (33.9) vs 123 (37.1) 0.91 (0.74–1.11)
SPTB<34 weeks 42 (16.6) vs 64 (25.7) 5 (31.3) vs 6 (35.3)* 14 (17.7) vs 13 (19.7) 61 (17.5) vs 83 (25.0) 0.71 (0.53–0.95)†
SPTB<32 weeks 21 (8.3) vs 35 (14.1) 0 (0) vs 4 (23.5)* 10 (12.7) vs 9 (13.6)* 31 (8.9) vs 48 (14.5) 0.62 (0.40–0.94)†
SPTB<28 weeks 8 (3.2) vs 9 (3.6) 0 (0) vs 0 (0)* 8 (10.1) vs 7 (10.6)* 16 (4.6) vs 16 (4.8) 0.91 (0.44–1.86)
SPTB<24 weeks 3 (1.2) vs 3 (1.2) 0 (0) vs 0 (0)* 4 (5.1) vs 2 (3.0)* 7 (2.0) vs 5 (1.5) 1.27 (0.41–3.98)
Adverse drug
reaction
19 (7.5) vs 35 (14.1) 0 (0) vs 0 (0)* NA 19/269 (7.1) vs
35/266 (13.2)
0.53 (0.31–0.91)†
Birth weight (g) 2637 ± 737 vs
2562 ± 780
2514 ± 609 vs
2550 ± 912*
2777 ± 1131 vs
2680 ± 840
— 72.32‡
(44.53–191.84)
Admission to NICU 39 (15.4) vs 64 (25.7) 7 (43.8) vs 2 (11.8)* 19 (24.1) vs 12 (18.2) 65 (18.7) vs 78 (23.5) 0.63 (0.47–0.83)†
RDS 19 (7.5) vs 26 (10.4) 7 (43.8) vs 2 (11.8)* 9 (11.4) vs 5 (7.6) 35 (10.1) vs 33 (9.9) 1.02 (0.65–1.60)
BPD 3 (1.2) vs 4 (1.6) 0 (0) vs 0 (0)* 1 (1.3) vs 0 (0)* 4 (1.2) vs 4 (1.2) 0.95 (0.26–3.51)
IVH 5 (2.0) vs 5 (2.0) 0 (0) vs 0 (0)* 1 (1.3) vs 4 (6.1)* 6/348 (1.7) vs 9/315 (2.9) 0.62 (0.23–1.71)
NEC 3 (1.2) vs 2 (0.8) 0 (0) vs 0 (0)* 1 (1.3) vs 2 (3.0) 4 (1.2) vs 4 (1.2) 0.93 (0.24–3.62)
Sepsis 5 (2.0) vs 4 (1.6) 0 (0) vs 1 (5.9)* 1 (1.3) vs 3 (4.5)* 6 (1.7) vs 8 (2.4) 0.73 (0.27–1.99)
Perinatal death 6 (2.4) vs 10 (4.0) 0 (0) vs 0 (0)* 5 (6.3) vs 7 (10.6) 11 (3.2) vs 17 (5.1) 0.59 (0.28–1.24)
Data are given as n (%) or mean ± SD for vaginal progesterone vs 17-OHPC. *Additional unpublished data obtained from authors of
original trials. †Statistically significant. ‡Mean difference (MD). BPD, bronchopulmonary dysplasia; IVH, intraventricular hemorrhage;
NA, not available; NEC, necrotizing enterocolitis; NICU, neonatal intensive care unit; RDS, respiratory distress syndrome; RR, relative risk.
Maher (2012)10
Study or subgroup
Vaginal
Events Total Events Total
17-OHPC Risk ratio
M–H, random (95% CI) M–H, random, 95% CI
Risk ratio
Weight
Bafghi (2015)12
Elimian (2016)11
42
5
14
253
16
79
64
6
13
249
17
66
72.0%
9.2%
18.8%
61
348
83
332 100.0%
0.65 (0.46, 0.91)
0.89 (0.34, 2.34)
0.90 (0.46, 1.78)
0.71 (0.53, 0.95)
0.2 0.5
Favors vaginal
progesterone
Favors
17-OHPC
1 2 5
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.95, df = 2 (P = 0.62); I2 = 0%
Test for overall effect: Z = 2.30 (P = 0.02)
Figure 3 Forest plot for risk of recurrent spontaneous preterm birth (SPTB)<34 weeks in women with singleton pregnancy and prior SPTB
randomized to vaginal progesterone or intramuscular 17α-hydroxyprogesterone caproate (17-OHPC) injection. Only first author of each
study is given. M–H, Mantel–Haenszel test.
published so far on this topic, including studies of high
quality and with a low risk of bias, according to the
Cochrane risk of bias tools. The statistical heterogeneity
within the studies was low.
A limitation of our study is that we found only three tri-
als that met the inclusion criteria. Furthermore, different
doses of daily vaginal progesterone (90 mg gel, and 100
and 200 mg suppository) were used in each study, making
it unclear which of these doses and/or formulations of
vaginal progesterone should be preferred. Many out-
comes were underpowered, including neonatal outcomes;
however, these are indeed uncommon outcomes with an
overall low incidence. None of the included trials was
double blinded. Blinding could have been accomplished
if a placebo had been utilized in each treatment arm. This
was therefore a considerable source of bias that may have
affected treatment of these women or their neonates.
Given that there were only three trials and the majority of
data were from only one of these studies, there was little
power to discern significant heterogeneity and therefore
to posit which model (fixed vs random effects) was the
proper one. More than half of the women included in the
analysis (502/680) were from one large study10, which
therefore drives the summary statistics7. We included the
two smaller studies in order to allow for a more powerful
analysis, especially for secondary outcomes.
Quality of evidence
The quality of evidence for each outcome is summarized in
Table S1. For comparison of 17-OHPC vs vaginal proges-
terone, the quality of evidence was downgraded because
of serious imprecision. Primary and secondary outcomes
were imprecise because studies included relatively few
patients with few events and thus had wide CIs around
the estimate of the effect, and because the optimal infor-
mation size was not reached. The quality of the evidence
was also downgraded another level because of serious
indirectness, owing to the different interventions used8.
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Implications
The American College of Obstetricians and Gynecologists
(ACOG) and the Society for Maternal Fetal Medicine
(SMFM) both recommend the use of 17-OHPC to prevent
recurrent SPTB3,4. Data on the efficacy of 17-OHPC
have generally been published earlier than data on the
efficacy of vaginal progesterone, regarding comparison
of these administration routes to placebo2,5,6,15,16. So far,
four trials have compared weekly intramuscular injections
with placebo or routine care and five have studied vaginal
progesterone, as per the latest Cochrane Review in women
with prior SPTB6.
Most recently, a new large randomized study, the
OPPTIMUM study, did not find significant effect of
vaginal progesterone on prevention of preterm birth
in 1228 women at risk of SPTB due to three major
risk factors: prior SPTB; positive fetal fibronectin test;
or short CL (< 25 mm) on transvaginal ultrasound17.
It is noteworthy that the OPPTIMUM study was
underpowered to detect a meaningful difference between
vaginal progesterone and placebo in the subgroup of
women with a short cervix, with a post-hoc statistical
power of only 26% to detect a 23% reduction in
the risk of SPTB< 34 weeks17. In a meta-analysis of
five RCTs, including the OPPTIMUM study, Romero
et al. showed that in women with a mid-trimester
short CL, progesterone is associated with a significant
reduction in the risk of preterm delivery and neonatal
morbidity and mortality, without any deleterious effects
on neurodevelopmental outcome18.
As both routes have been shown to be effective against
placebo in women with singleton gestation and prior
SPTB2,5,6, the next question to consider is how they
compare with each other. Some studies have shown that
natural progesterone, including vaginal progesterone, is
preferable because of a lack of undesirable side effects,
such as sleepiness, fatigue and headaches, compared with
synthetic progestogens, including 17-OHPC19. Addition-
ally, there is some concern that injection of 17-OHPC
may increase the risk of early fetal death19,20. Our study
showed a non-significant 29% reduction in perinatal
death in women who received vaginal progesterone
compared with 17-OHPC; however, our meta-analysis
was not sufficiently powered for such a rare outcome.
The fact that vaginal progesterone was associated with
lower rates of SPTB, fewer adverse side effects and
neonatal benefits compared with intramuscular 17-OHPC
needs to be correlated with cost-effectiveness. While no
data on cost-effectiveness were reported in the three
included trials, the cost of vaginal progesterone (about
$11/day or about $77/week)21 is much lower than that of
17-OHPC (> $500/week)22 in the USA.
Conclusion
Compared with intramuscular 17-OHPC, vaginal proges-
terone in women with prior SPTB is associated with
at least seven benefits: (1) reduced risk of recurrent
SPTB10–12; (2) fewer adverse maternal side effects10–12;
(3) fewer NICU admissions10–12; (4) lower cost21,22;
(5) better compliance10,12,23; (6) women’s preferred
choice12,21; and (7) greater satisfaction9,23.
In summary, we consider daily vaginal progesterone
(suppository or gel) a reasonable, if not better, alternative
therapy to weekly intramuscular 17-OHPC for prevention
of SPTB in women with asymptomatic singleton preg-
nancy and prior SPTB. Given the clear and positive effect
of progestogen in women with prior SPTB, we suggest
offering 250 mg 17-OHPC weekly or 90–200 mg vaginal
progesterone daily, starting from 16 weeks and continuing
until 36 weeks or delivery, to asymptomatic women with
prior SPTB. However, the quality levels of the summary
estimates were low/very low, as assessed by GRADE,
indicating that the true effect may be, or is likely to be,
substantially different from the estimate of the effect.
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Comparaci o´n entre la progesterona vaginal y el 17α-hidroxiprogesterona caproato intramuscular
para la prevenci o´n del parto pret e´rmino esponta´neo recurrente en embarazos con feto u´nico:
revis i o´n sistema´t ica y metaana´l is is de ensayos controlados aleatorios
RESUMEN
Objetivo Recientemente se han realizado varios ensayos controlados aleatorios (ECA) que comparaban el caproato de
17α-hidroxiprogesterona (17-OHPC, por sus siglas en ingle´s) por vı´a intramuscular con la progesterona por vı´a vaginal
para la reduccio´n del riesgo de parto prete´rmino esponta´neo (PPTE) en embarazos con feto u´nico de gestantes con historial de
PPTE. El objetivo de esta revisio´n sistema´tica y metaana´lisis fue evaluar la eficacia de la progesterona vaginal en comparacio´n
con la 17-OHPC en la prevencio´n de embarazos con feto u´nico de gestantes con historial de PPTE.
Me´todos Se realizaron bu´squedas en bases de datos electro´nicas para identificar todos los ECA con embarazos de feto u´nico
asintoma´ticos con historial de PPTE antes de ser asignados al azar a un tratamiento profila´ctico, ya fuera con progesterona vaginal
(grupo de intervencio´n) o con 17-OHPC intramuscular (grupo de control). No se aplicaron restricciones respecto al idioma o la
ubicacio´n geogra´fica. El resultado primario fue PPTE < 34 semanas. Los resultados secundarios fueron PPTE <37 semanas, <
32 semanas, < 28 semanas y<24 semanas, la reaccio´n materna adversa al fa´rmaco y los resultados neonatales. Las medidas del
resumen se reportaron como riesgo relativo (RR) con IC del 95%. Para cada estudio incluido se evaluo´ el riesgo de sesgo.
Resultados Se incluyeron tres ECA (680 mujeres). La media de la edad gestacional en el momento de la aleatorizacio´n fue de
16 semanas. A las mujeres se les administro´ progesterona hasta la semana 36 o hasta el parto. Con respecto a la progesterona
vaginal, un estudio utilizo´ gel de 90 mg diariamente, otro utilizo´ un supositorio diario de 100 mg y el otro utilizo´ un supositorio
diario de 200 mg. Todos los ECA incluidos en el grupo de comparacio´n utilizaron 250 mg semanales de 17-OHPC por vı´a
intramuscular. Las mujeres que recibieron progesterona vaginal tuvieron tasas significativamente ma´s bajas de PPTE < 34
semanas (17,5% vs. 25,0%; RR 0,71 (IC 95%, 0,53–0,95); calidad de la evidencia baja) y<32 semanas (8,9% vs. 14,5%;
RR 0,62 (IC 95%, 0,40–0,94); calidad de evidencia baja), en comparacio´n con las mujeres que recibieron 17-OHPC. No hubo
diferencias significativas en las tasas de PPTE < 37 semanas, < 28 semanas y< 24 semanas. La tasa de mujeres que reportaron
reacciones adversas a los medicamentos fue significativamente menor en el grupo de progesterona vaginal en comparacio´n con
el grupo de 17-OHPC (7,1% vs. 13,2%; RR 0,53 (IC 95%, 0,31–0,91); calidad de la evidencia muy baja). En cuanto a los
resultados neonatales, la progesterona vaginal se asocio´ a una menor tasa de admisiones en la unidad neonatal de cuidados
intensivos en comparacio´n con la 17-OHPC (18,7% vs. 23,5%; RR 0,63 (IC 95%, 0,47–0,83); calidad de evidencia baja). Para
la comparacio´n del 17-OHPC con la progesterona vaginal se rebajo´ la calidad de las pruebas para todos los resultados en al
menos un grado debido a imprecisiones (no se alcanzo´ el taman˜o o´ptimo de la informacio´n) y en al menos un grado debido al
cara´cter indirecto de los estudios (diferentes intervenciones).
Conclusiones La progesterona vaginal administrada diariamente (ya fuera como supositorio o como gel) desde la semana 16 de
gestacio´n es una alternativa razonable, si no mejor, a una inyeccio´n semanal de 17-OHPC para la prevencio´n de PPTE en mujeres
con embarazos de feto u´nico e historial de PPTE. Sin embargo, el nivel de calidad de las estimaciones del resumen fue bajo o
muy bajo segu´n lo evaluado por GRADE, lo que indica que el verdadero efecto puede ser, o es probable que sea, sustancialmente
diferente de la estimacio´n del efecto.
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